Citi analyst Yigal Nochomovitz lowered the firm’s price target on Galera Therapeutics to $18 from $20 and keeps a Buy rating on the shares. The analyst updated his model post the Q3 results.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on GRTX: